Overview
HDL in type 2 diabetes is characterized by both quantitative (low HDL-C) and qualitative (dysfunctional HDL) abnormalities. HDL cholesterol efflux capacity, anti-inflammatory activity, anti-oxidative capacity, and vasoprotective functions are all impaired in T2D, driven by glycation, carbamylation, oxidation, and inflammatory remodeling of the HDL proteome and lipidome. These changes contribute to accelerated atherosclerosis and cardiovascular risk. HDL also exerts anti-diabetic effects — improving beta-cell function, insulin secretion, and insulin sensitivity — supporting the concept of HDL-based therapeutics that target HDL function rather than HDL-C levels.
Key Findings
-
Low HDL-C is a hallmark of diabetic dyslipidemia in T2D, but HDL-C is a poor surrogate for HDL functionality. HDL-C levels show a U-shaped association with cardiovascular risk, and Mendelian randomization studies give mixed evidence for causality — some showing a causal protective effect (European, African ancestry) and others not (East Asian). Lui & Tan 2024
-
Cholesterol efflux capacity (CEC) is reduced in T2D in most, but not all, studies. ABCA1-mediated efflux to small HDL is selectively attenuated due to reduced SERPINA1 content in small HDL particles. A meta-analysis of 10+ studies shows ~10% reduction in CEC in T2D. However, some well-controlled T2D cohorts show preserved CEC, depending on glycemic control and patient selection.
-
HDL anti-inflammatory function is impaired in T2D, characterized by reduced ability to inhibit TNFα-induced VCAM-1/ICAM-1 expression on endothelial cells and reduced capacity to suppress cytokine release from macrophages. Key drivers: SAA enrichment (converting HDL to pro-inflammatory), PON1 depletion, glycation of apoA-I, and MPO-mediated oxidation.
-
HDL particle subfractions shift toward smaller, denser particles in T2D: reduced large HDL2, increased small HDL3. CETP upregulation drives triglyceride enrichment and cholesteryl ester depletion in HDL cores, making particles susceptible to hepatic lipase and leading to apoA-I loss. This shift limits the capacity for efficient reverse cholesterol transport.
-
HDL exerts anti-diabetic effects on beta-cells: HDL and apoA-I increase insulin synthesis and glucose-stimulated insulin secretion via the G-protein–cAMP–PKA–FoxO1 pathway, upregulate the beta-cell survival gene PDX1, and protect beta-cells from gluco/lipotoxicity-induced apoptosis. Reconstituted HDL infusion (rHDL) acutely improves glycemic control in T2D patients.
-
CETP inhibitors consistently reduce new-onset diabetes risk by ~16% (RR 0.84, 95% CI 0.78–0.91) across 4 major trials, suggesting that HDL-raising therapies may have anti-diabetic effects independent of their cardiovascular impact. Obicetrapib (phase 3) reduced HbA1c and showed a trend toward lower new-onset diabetes.
-
South Asian ancestry is associated with the lowest HDL-C levels among Asian ethnic groups, contributing to the “South Asian phenotype” of high T2D risk at lower BMI. Mendelian randomization confirms a causal protective effect of HDL-C in African ancestry individuals (OR 0.915 per SD), but studies in East Asian populations are inconclusive.
-
HDL immunomodulation is relevant to PBMC biology: HDL suppresses monocyte CD11b expression, reduces macrophage pro-inflammatory cytokine secretion, promotes M2 macrophage polarization, and modulates T-cell antigen presentation via cholesterol efflux. In T2D, these immunomodulatory functions are impaired.
Core Concepts
- HDL Dysfunction in Type 2 Diabetes — The concept that HDL particles in T2D are structurally and functionally impaired, losing cardioprotective and immunomodulatory activities.
- HDL Cholesterol Efflux Capacity — The ability of HDL to accept cholesterol from macrophages via ABCA1, ABCG1, and SR-BI; reduced in T2D and independently associated with CVD risk.
- HDL Anti-Inflammatory Function — The ability of HDL to suppress endothelial adhesion molecule expression, inhibit macrophage cytokine release, and modulate monocyte recruitment; impaired by SAA enrichment and PON1 depletion in T2D.
- HDL and Beta-Cell Function — The anti-diabetic effects of HDL on pancreatic beta-cells: enhanced insulin secretion, beta-cell survival, and PDX1 expression via the cAMP-PKA-FoxO1 pathway.
- HDL Particle Subfractions in T2D — The shift from large, cholesterol-rich HDL2 to small, dense HDL3 particles in T2D, driven by CETP-mediated triglyceride enrichment.
- HDL Glycation and Inflammation in T2D — How non-enzymatic glycation, carbamylation, and MPO-induced oxidation modify HDL, impairing its functions in T2D.
Entities & Tools
- CETP (Cholesteryl Ester Transfer Protein) — Enzyme mediating CE/TG exchange between HDL and apoB-containing lipoproteins; upregulated in T2D, driving the shift to small HDL; therapeutic target for CETP inhibitors.
- ApoA-I (Apolipoprotein A-I) — The major structural and functional protein of HDL; subject to glycation, oxidation, and carbamylation in T2D; mediates many of HDL’s anti-atherogenic and anti-diabetic effects.
- PON1 (Paraoxonase-1) — HDL-associated antioxidant enzyme; reduced activity in T2D impairs HDL’s anti-oxidative and anti-inflammatory capacities.
- CSL112 — Reconstituted HDL (rHDL) therapeutic in phase 3 AEGIS-II trial for secondary CVD prevention; enhances cholesterol efflux capacity.
- Obicetrapib — CETP inhibitor in phase 3 trials; shown to reduce HbA1c and new-onset diabetes risk; raises HDL-C by ~137%.
Contradictions & Open Questions
-
CEC preservation in some T2D cohorts: Denimal et al. 2022 found preserved CEC and anti-inflammatory capacity in well-controlled T2D despite lipidomic abnormalities. This suggests HDL dysfunction may be modifiable and dependent on glycemic control, not an inevitable consequence of T2D.
-
Anti-inflammatory capacity measurement varies by assay and cell type: The degree of impairment depends on the HDL isolation method (ultracentrifugation vs. PEG precipitation), the cell type (HCAEC vs. REC vs. HUVEC), and whether total HDL or specific subfractions are tested.
-
MR evidence is ancestry-specific: HDL-C is causally protective in European and African ancestry populations, but East Asian MR studies do not find a significant causal relationship. This may reflect differences in HDL particle distribution, CETP activity, or genetic architecture by ancestry.
-
CETP inhibitors raise HDL-C but do not reduce CV events — yet do reduce new-onset diabetes: This paradox suggests the glycemic benefit of CETP inhibition may be mediated by mechanisms distinct from HDL-C levels, possibly via CETP’s effects on VLDL/LDL metabolism or direct effects on beta-cell cholesterol homeostasis.
-
HDL-C levels alone do not predict HDL functionality: The U-shaped association between HDL-C and mortality, and the failure of HDL-raising therapies (niacin, most CETP inhibitors) to reduce CV events, underscore that HDL function — not HDL-C concentration — is the clinically relevant metric.
Sources Consulted
- Lui & Tan 2024 — High-density lipoprotein in diabetes: Structural and functional relevance — Comprehensive JDI review covering HDL composition, subfractions, dysfunction in T1D/T2D, and anti-diabetic effects.
- Denimal et al. 2022 — Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in T2D Despite Lipidomic Abnormalities (PMID: 35967794). Primary study showing preserved HDL function in well-controlled T2D.
- Cardner et al. (JCI Insight) — Structure-function relationships of HDL in diabetes and CHD. Comprehensive multi-omics study showing weak correlation among HDL functions and distinct structural determinants.
- MDPI Cells 2024 review — HDL Modifications in T2DM: Causes and Functional Consequences. Detailed coverage of glycation, carbamylation, and oxidation of HDL.
- MDPI Metabolites 2023 review — HDL Alterations in T2D and Obesity. Subfraction shifts, CETP, and lipidomic changes.
- NHANES + MR 2024 (Frontiers Endocrinology) — MR evidence for causal HDL-C–T2D relationship.
- Haase et al. 2021 (CETP inhibitor meta-analysis, PMC9729761) — CETP inhibitors reduce new-onset diabetes by 16%.
- Singapore Multi-Ethnic Cohort 2023 — Ethnic differences in HDL-C across Chinese, Malay, Indian groups, with Indians having lowest HDL-C and highest T2D risk.
- APCDR + MVP 2022 MR — HDL-C causally protective in African ancestry individuals.
- Biobank Japan MR 2022 — No causal HDL-C–T2D association in East Asians.